StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 14:46:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Qiagen (QGEN) spreader of 10K contracts of August 40 and 20K contracts of August 45 calls http://www.streetinsider.com/Options/Qiagen+%28QGEN%29+spreader+of+10K+contracts+of+August+40+and+20K+contracts+of+August+45+calls/26819027.html <p>Qiagen (NYSE: QGEN) 30-day call option implied volatility is 54; compared to its 52-week range of 18 to 59 with a focus on a spreader of 10K contracts of August 40 and 20K contracts of August 45 calls. </p> http://www.streetinsider.com/Options/Qiagen+%28QGEN%29+spreader+of+10K+contracts+of+August+40+and+20K+contracts+of+August+45+calls/26819027.html Mon, 27 Jul 2026 14:46:21 -0400 QGEN QIAGEN touts Cyclospora detection tools amid U.S. outbreak http://www.streetinsider.com/Corporate+News/QIAGEN+touts+Cyclospora+detection+tools+amid+U.S.+outbreak/26774130.html <p>QIAGEN N.V. (NYSE: QGEN) highlighted its molecular testing products for detecting <em>Cyclospora cayetanensis</em> as U.S. health authorities report more than 1,600 confirmed cases of cyclosporiasis since May 2026, along with approximately 7,000 potential cases, according to a company press release.</p><p>The foodborne parasite, which can cause prolonged diarrhea and other gastrointestinal symptoms, is not detectable through routine stool culture and requires specialized diagnostic methods.</p><p>The company's FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes <em>Cyclospora cayetanensis</em> as one of 16 targets covering bacterial, viral, and parasitic pathogens. The test delivers results in approximately one hour from a single patient sample.</p><p>For research use only, QIAGEN http://www.streetinsider.com/Corporate+News/QIAGEN+touts+Cyclospora+detection+tools+amid+U.S.+outbreak/26774130.html Wed, 15 Jul 2026 16:05:55 -0400 QGEN QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak http://www.streetinsider.com/Press+Releases/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html <ul class="bwlistdisc"> <li> <b>More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations</b> </li> </ul> <p> GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis http://www.streetinsider.com/Press+Releases/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html Wed, 15 Jul 2026 16:05:00 -0400 O.00543542 QGEN QIA QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak http://www.streetinsider.com/Press+Releases/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html <ul class="bwlistdisc"> <li> <b>More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations</b> </li> </ul> <p> GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis http://www.streetinsider.com/Press+Releases/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html Wed, 15 Jul 2026 16:05:00 -0400 O.00543542 QGEN QIA QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak http://www.streetinsider.com/Press+Releases/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html <ul class="bwlistdisc"> <li> <b>More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations</b> </li> </ul> <p> GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis http://www.streetinsider.com/Press+Releases/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html Wed, 15 Jul 2026 16:05:00 -0400 O.00543542 QGEN QIA QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak http://www.streetinsider.com/Business+Wire/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html <ul class="bwlistdisc"> <li> <b>More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations</b> </li> </ul> <p> GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis http://www.streetinsider.com/Business+Wire/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html Wed, 15 Jul 2026 16:05:00 -0400 O.00543542 QGEN QIA QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak http://www.streetinsider.com/Business+Wire/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html <ul class="bwlistdisc"> <li> <b>More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations</b> </li> </ul> <p> GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis http://www.streetinsider.com/Business+Wire/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html Wed, 15 Jul 2026 16:05:00 -0400 O.00543542 QGEN QIA QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak http://www.streetinsider.com/Business+Wire/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html <ul class="bwlistdisc"> <li> <b>More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu</b> </li> </ul><ul class="bwlistdisc"> <li> <b>QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations</b> </li> </ul> <p> GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis http://www.streetinsider.com/Business+Wire/QIAGEN+Highlights+Molecular+Testing+Solutions+Supporting+Response+to+Growing+U.S.+Cyclospora+Outbreak/26774088.html Wed, 15 Jul 2026 16:05:00 -0400 O.00543542 QGEN QIA QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast http://www.streetinsider.com/Press+Releases/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. </p><p> Press release date / time: <b>Wednesday, August 5</b> shortly after <b>22:05</b> <b>Frankfurt time / 21:05 London time / 16:05 New York time.</b> </p><p> Conference call date / time: <b>Thursday,</b> <b>August 6</b>, at <b>15:30 Frankfurt time / 14:30 London time / 09:30 New York time.</b> </p><p> <b><span class="bwuline">Three options for joining the </span><span class="bwuline">conference call</span></b> </p><p class="bwmarginl1"> <b>Register for call back connection - </b>Click here: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fmyconferencinghub.com%252Fclick-to-join%252F2545624%26data%3D05%257C02%257CAlexandra.Koenig%2540qiagen.com%257C0a3075a2593540e3a48d08dec0ae83ad%257Cdc81d03c239c4fd5a96f18a58773c86c%257C0%257C0%257C639160052919410667%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C4000%257C%257C%257C%26sdata%3De%252FkGZSUCWl0dTZOdrw%252FU68yQ%252BycGeh0waxBCfFKmP%252Bc%253D%26reserved%3D0&esheet=54570921&newsitemid=20260715523254&lan=en-US&anchor=Connect+me&index=1&md5=2b1a144a3c0604e2befe98cc958f2d7d" shape="rect"><b>Connect me </b></a><b><br /></b>Service is available 15 minutes before the call starts </p><p class="bwmarginl1"> <b>Dial-in by http://www.streetinsider.com/Press+Releases/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html Wed, 15 Jul 2026 08:48:00 -0400 O.00543542 QGEN QIA QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast http://www.streetinsider.com/Press+Releases/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. </p><p> Press release date / time: <b>Wednesday, August 5</b> shortly after <b>22:05</b> <b>Frankfurt time / 21:05 London time / 16:05 New York time.</b> </p><p> Conference call date / time: <b>Thursday,</b> <b>August 6</b>, at <b>15:30 Frankfurt time / 14:30 London time / 09:30 New York time.</b> </p><p> <b><span class="bwuline">Three options for joining the </span><span class="bwuline">conference call</span></b> </p><p class="bwmarginl1"> <b>Register for call back connection - </b>Click here: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fmyconferencinghub.com%252Fclick-to-join%252F2545624%26data%3D05%257C02%257CAlexandra.Koenig%2540qiagen.com%257C0a3075a2593540e3a48d08dec0ae83ad%257Cdc81d03c239c4fd5a96f18a58773c86c%257C0%257C0%257C639160052919410667%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C4000%257C%257C%257C%26sdata%3De%252FkGZSUCWl0dTZOdrw%252FU68yQ%252BycGeh0waxBCfFKmP%252Bc%253D%26reserved%3D0&esheet=54570921&newsitemid=20260715523254&lan=en-US&anchor=Connect+me&index=1&md5=2b1a144a3c0604e2befe98cc958f2d7d" shape="rect"><b>Connect me </b></a><b><br /></b>Service is available 15 minutes before the call starts </p><p class="bwmarginl1"> <b>Dial-in by http://www.streetinsider.com/Press+Releases/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html Wed, 15 Jul 2026 08:48:00 -0400 O.00543542 QGEN QIA QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast http://www.streetinsider.com/Press+Releases/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. </p><p> Press release date / time: <b>Wednesday, August 5</b> shortly after <b>22:05</b> <b>Frankfurt time / 21:05 London time / 16:05 New York time.</b> </p><p> Conference call date / time: <b>Thursday,</b> <b>August 6</b>, at <b>15:30 Frankfurt time / 14:30 London time / 09:30 New York time.</b> </p><p> <b><span class="bwuline">Three options for joining the </span><span class="bwuline">conference call</span></b> </p><p class="bwmarginl1"> <b>Register for call back connection - </b>Click here: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fmyconferencinghub.com%252Fclick-to-join%252F2545624%26data%3D05%257C02%257CAlexandra.Koenig%2540qiagen.com%257C0a3075a2593540e3a48d08dec0ae83ad%257Cdc81d03c239c4fd5a96f18a58773c86c%257C0%257C0%257C639160052919410667%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C4000%257C%257C%257C%26sdata%3De%252FkGZSUCWl0dTZOdrw%252FU68yQ%252BycGeh0waxBCfFKmP%252Bc%253D%26reserved%3D0&esheet=54570921&newsitemid=20260715523254&lan=en-US&anchor=Connect+me&index=1&md5=2b1a144a3c0604e2befe98cc958f2d7d" shape="rect"><b>Connect me </b></a><b><br /></b>Service is available 15 minutes before the call starts </p><p class="bwmarginl1"> <b>Dial-in by http://www.streetinsider.com/Press+Releases/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html Wed, 15 Jul 2026 08:48:00 -0400 O.00543542 QGEN QIA QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast http://www.streetinsider.com/Business+Wire/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. </p><p> Press release date / time: <b>Wednesday, August 5</b> shortly after <b>22:05</b> <b>Frankfurt time / 21:05 London time / 16:05 New York time.</b> </p><p> Conference call date / time: <b>Thursday,</b> <b>August 6</b>, at <b>15:30 Frankfurt time / 14:30 London time / 09:30 New York time.</b> </p><p> <b><span class="bwuline">Three options for joining the </span><span class="bwuline">conference call</span></b> </p><p class="bwmarginl1"> <b>Register for call back connection - </b>Click here: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fmyconferencinghub.com%252Fclick-to-join%252F2545624%26data%3D05%257C02%257CAlexandra.Koenig%2540qiagen.com%257C0a3075a2593540e3a48d08dec0ae83ad%257Cdc81d03c239c4fd5a96f18a58773c86c%257C0%257C0%257C639160052919410667%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C4000%257C%257C%257C%26sdata%3De%252FkGZSUCWl0dTZOdrw%252FU68yQ%252BycGeh0waxBCfFKmP%252Bc%253D%26reserved%3D0&esheet=54570921&newsitemid=20260715523254&lan=en-US&anchor=Connect+me&index=1&md5=2b1a144a3c0604e2befe98cc958f2d7d" shape="rect"><b>Connect me </b></a><b><br /></b>Service is available 15 minutes before the call starts </p><p class="bwmarginl1"> <b>Dial-in by http://www.streetinsider.com/Business+Wire/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html Wed, 15 Jul 2026 08:48:00 -0400 O.00543542 QGEN QIA QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast http://www.streetinsider.com/Business+Wire/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. </p><p> Press release date / time: <b>Wednesday, August 5</b> shortly after <b>22:05</b> <b>Frankfurt time / 21:05 London time / 16:05 New York time.</b> </p><p> Conference call date / time: <b>Thursday,</b> <b>August 6</b>, at <b>15:30 Frankfurt time / 14:30 London time / 09:30 New York time.</b> </p><p> <b><span class="bwuline">Three options for joining the </span><span class="bwuline">conference call</span></b> </p><p class="bwmarginl1"> <b>Register for call back connection - </b>Click here: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fmyconferencinghub.com%252Fclick-to-join%252F2545624%26data%3D05%257C02%257CAlexandra.Koenig%2540qiagen.com%257C0a3075a2593540e3a48d08dec0ae83ad%257Cdc81d03c239c4fd5a96f18a58773c86c%257C0%257C0%257C639160052919410667%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C4000%257C%257C%257C%26sdata%3De%252FkGZSUCWl0dTZOdrw%252FU68yQ%252BycGeh0waxBCfFKmP%252Bc%253D%26reserved%3D0&esheet=54570921&newsitemid=20260715523254&lan=en-US&anchor=Connect+me&index=1&md5=2b1a144a3c0604e2befe98cc958f2d7d" shape="rect"><b>Connect me </b></a><b><br /></b>Service is available 15 minutes before the call starts </p><p class="bwmarginl1"> <b>Dial-in by http://www.streetinsider.com/Business+Wire/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html Wed, 15 Jul 2026 08:48:00 -0400 O.00543542 QGEN QIA QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast http://www.streetinsider.com/Business+Wire/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. </p><p> Press release date / time: <b>Wednesday, August 5</b> shortly after <b>22:05</b> <b>Frankfurt time / 21:05 London time / 16:05 New York time.</b> </p><p> Conference call date / time: <b>Thursday,</b> <b>August 6</b>, at <b>15:30 Frankfurt time / 14:30 London time / 09:30 New York time.</b> </p><p> <b><span class="bwuline">Three options for joining the </span><span class="bwuline">conference call</span></b> </p><p class="bwmarginl1"> <b>Register for call back connection - </b>Click here: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fmyconferencinghub.com%252Fclick-to-join%252F2545624%26data%3D05%257C02%257CAlexandra.Koenig%2540qiagen.com%257C0a3075a2593540e3a48d08dec0ae83ad%257Cdc81d03c239c4fd5a96f18a58773c86c%257C0%257C0%257C639160052919410667%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C4000%257C%257C%257C%26sdata%3De%252FkGZSUCWl0dTZOdrw%252FU68yQ%252BycGeh0waxBCfFKmP%252Bc%253D%26reserved%3D0&esheet=54570921&newsitemid=20260715523254&lan=en-US&anchor=Connect+me&index=1&md5=2b1a144a3c0604e2befe98cc958f2d7d" shape="rect"><b>Connect me </b></a><b><br /></b>Service is available 15 minutes before the call starts </p><p class="bwmarginl1"> <b>Dial-in by http://www.streetinsider.com/Business+Wire/QIAGEN+N.V.+to+Release+Results+for+Q2+2026+and+Hold+Webcast/26771590.html Wed, 15 Jul 2026 08:48:00 -0400 O.00543542 QGEN QIA Qiagen launches new bloodstream infection panel in Europe http://www.streetinsider.com/Corporate+News/Qiagen+launches+new+bloodstream+infection+panel+in+Europe/26768298.html <p>Qiagen N.V. (NYSE: QGEN) has launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, a diagnostic test that detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures.</p><p>The new panel delivers results in about one hour and complements the previously launched QIAstat-Dx BCID GPF Plus AMR Panel. Together, the two panels detect 33 pathogen targets and 28 antimicrobial resistance markers, covering gram-positive bacteria, gram-negative bacteria, fungi and key resistance markers.</p><p>"Every hour matters when treating bloodstream infections, particularly when AMR is involved," said Nitin Sood, Senior Vice President and Head of Product Portfolio & http://www.streetinsider.com/Corporate+News/Qiagen+launches+new+bloodstream+infection+panel+in+Europe/26768298.html Tue, 14 Jul 2026 16:07:03 -0400 QGEN QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Press+Releases/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html <ul class="bwlistdisc"> <li> <b>New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18</b> <b>antimicrobial resistance markers from positive blood cultures</b> </li> <li> <b>Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing</b> </li> <li> <b>QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts</b> </li> <li> <b>Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion</b> </li> </ul> <p> VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the http://www.streetinsider.com/Business+Wire/QIAGEN+Expands+QIAstat-Dx+Bloodstream+Infection+Testing+Menu+in+Europe/26768248.html Tue, 14 Jul 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA